ASSOCIATION OF DEFICIENCY IN ANTIBODY-RESPONSE TO VACCINE AND HETEROGENEITY OF EHRLICHIA-RISTICII STRAINS WITH POTOMAC HORSE FEVER VACCINE FAILURE IN HORSES
Sk. Dutta et al., ASSOCIATION OF DEFICIENCY IN ANTIBODY-RESPONSE TO VACCINE AND HETEROGENEITY OF EHRLICHIA-RISTICII STRAINS WITH POTOMAC HORSE FEVER VACCINE FAILURE IN HORSES, Journal of clinical microbiology, 36(2), 1998, pp. 506-512
Ehrlichia risticii is the causative agent of Potomac horse fever (PI-I
F), which continues to be an important disease of horses, Commercial i
nactivated whole-cell vaccines are regularly used for immunization of
horses against the disease. However, PHF is occurring in large numbers
of horses in spite of vaccination. In a limited study, 43 confirmed c
ases of PHF occurred between the 1994 and 1996 seasons; of these, 38 (
89%) were in horses that had been vaccinated for the respective season
, thereby clearly indicating vaccine failure. A field study of horses
vaccinated with two PHF vaccines indicated a poor antibody response, a
s determined by immunofluorescence assay (IFA) titers. In a majority o
f horses, the final antibody titer ranged between 40 and 1,280, in spi
te of repeated vaccinations. None of the vaccinated horses developed i
n vitro neutralizing antibody in their sera. Similarly, one horse expe
rimentally vaccinated three times with one of the vaccines showed a po
or antibody response, with final IFA titers between 80 and 160. The ho
rse did not develop in vitro neutralizing antibody or antibody against
the 50/85-kDa strain-specific antigen (SSA), which is the protective
antigen of the original strain, 25-D, and the variant strain of our la
boratory, strain 90-12. Upon challenge infection with the 90-12 strain
, the horse showed clinical signs of the disease. The horse developed
neutralizing antibody and antibody to the 50/85-kDa SSA following the
infection. Studies of the new E. risticii isolates from the field case
s indicated that they were heterogeneous among themselves and showed d
ifferences from the 25-D and 90-12 strains as determined by IFA reacti
vity pattern, DNA amplification finger printing profile, and in vitro
neutralization activity. Most importantly, the molecular sizes of the
SSA of these isolates varied, ranging from 48 to 85 kDa. These studies
suggest that the deficiency in the antibody response to the PI-IF vac
cines and the heterogeneity of E. risticii isolates may be associated
with the vaccine failure.